NATCO Pharma (Canada) announces US$ 8 million investment in eGenesis
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
eGenesis is pioneering a genome engineering-based approach in the development of safe and effective transplantable organs to end the global organ shortage
Mirabegron Extended-Release Tablets, 50 mg is a generic equivalent of Myrbetriq® Extended-Release Tablets, 50 mg of Astellas Pharma Global Development
Vonoprazan is used in the treatment of disorders related to Gastroesophageal Reflux Disease (GERD)
He will lead the final stages of work to commission the 54,000-square-foot facility and then lead ongoing operations at the site
New Phase II data show vast majority of patients experiencing no relapses or disability progression
The new facility further improves the operational efficiency and readies the site for the completion of the new large-scale production plant
PiaSky advances C5 inhibition through innovative recycling technology, which enables its monthly SC administration
Phase 3 study results will form the basis for future discussions with global regulatory authorities
Finerenone is the first mineralocorticoid receptor (MR) antagonist to demonstrate definitive cardiovascular benefits in a Phase III study in patients with heart failure (HF) with a left ventricular ejection fraction (LVEF) of ?40%
MyClad is a global Phase III study evaluating the efficacy and safety of cladribine capsules for the treatment of generalized Myasthenia Gravis (gMG)
Subscribe To Our Newsletter & Stay Updated